Itraconazole immediate release formulation
    3.
    发明申请
    Itraconazole immediate release formulation 审中-公开
    伊曲康唑立即释放制剂

    公开(公告)号:US20050074494A1

    公开(公告)日:2005-04-07

    申请号:US10679760

    申请日:2003-10-06

    CPC分类号: A61K31/496 A61K9/5078

    摘要: The present invention relates to active pellets without a specific inert starting seed size and without a seal coat, which may be compressed into a tablet or loaded into a capsule to form an orally administrable dosage formulation for an antifungal agent.

    摘要翻译: 本发明涉及不具有特定惰性起始种子大小并且没有密封涂层的活性丸粒,其可以压制成片剂或装载到胶囊中以形成用于抗真菌剂的可口服施用的剂型制剂。

    Controlled release metformin compositions
    4.
    发明授权
    Controlled release metformin compositions 有权
    对照释放二甲双胍组合物

    公开(公告)号:US06866866B1

    公开(公告)日:2005-03-15

    申请号:US09705630

    申请日:2000-11-03

    摘要: A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.

    摘要翻译: 一种用于治疗患有非胰岛素依赖性糖尿病(NIDDM)的患者的组合物,其通过每天一次地施用含有优选双胍类药物(例如二甲双胍)的控释口服固体剂型。 该剂型提供了在每天一次口服给予人类患者后5.5至7.5小时发生的药物最大血药浓度(Tmax)的平均时间。 优选地,在晚餐时间向给喂状态的患者施用药物剂量。

    Controlled release metformin compositions
    7.
    发明申请
    Controlled release metformin compositions 审中-公开
    对照释放二甲双胍组合物

    公开(公告)号:US20060008525A1

    公开(公告)日:2006-01-12

    申请号:US11225741

    申请日:2005-09-13

    IPC分类号: A61K9/22

    摘要: A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.

    摘要翻译: 一种用于治疗患有非胰岛素依赖性糖尿病(NIDM)的组合物,其通过每天一次地施用含有优选双胍类药物如二甲双胍的控释口服固体剂型。 该剂型提供了在每天一次给予人类患者的口服给药后5.5至7.5小时的药物的最大血浆浓度(T max max)的平均时间。 优选地,在晚餐时间向给喂状态的患者施用药物剂量。

    Diltiazem controlled release formulation and method of manufacture
    8.
    发明授权
    Diltiazem controlled release formulation and method of manufacture 失效
    地尔硫卓控制释放制剂和制造方法

    公开(公告)号:US06524620B2

    公开(公告)日:2003-02-25

    申请号:US09119323

    申请日:1998-07-20

    IPC分类号: A61K952

    摘要: A controlled release diltiazem dosage formulation comprising a plurality of active pellets coated with an extended release coating wherein the active pellets contain diltiazem or a pharmaceutically acceptable salt, a pharmaceutically acceptable inert seed and a binder and the extended release coating contains a water insoluble water permeable polymer, a channeling agent, a lubricant and optionally a surfactant. A single batch intermittent method of manufacturing a heterogeneous population of extended release pellets for use as a dosage formulation is also disclosed.

    摘要翻译: 一种受控释放的地尔硫卓剂量制剂,其包含涂覆有延长释放包衣的多个活性粒剂,其中活性丸剂含有地尔硫卓或其药学上可接受的盐,药学上可接受的惰性种子和粘合剂,并且延长释放包衣含有水不溶性水可渗透聚合物 沟道剂,润滑剂和任选的表面活性剂。 还公开了制造用作剂量制剂的不同种群的延长释放丸剂的单批次间歇方法。